The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Infectious Disease & AMR

Engineering the Microbiome to Treat Skin Diseases
Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

NOV 16, 2021
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Basic & Discovery Research

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

NOV 12, 2021
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
Finance

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

NOV 10, 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Clinical & Manufacturing

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

OCT 5, 2021
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection
Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

SEP 30, 2021
BiomX Inc. Announces $15 Million Registered Direct Offering
Finance

BiomX Inc. Announces $15 Million Registered Direct Offering

JUL 27, 2021
Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD
Finance

Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD

JUN 4, 2021
Global microbiome study discovers thousands of new species, maps urban antimicrobial resistance and reveals new drug candidates
Basic & Discovery Research

Global microbiome study discovers thousands of new species, maps urban antimicrobial resistance and reveals new drug candidates

JUN 3, 2021
Ben-Gurion University researchers developing probiotic yogurt-based drugs
Basic & Discovery Research

Ben-Gurion University researchers developing probiotic yogurt-based drugs

MAY 12, 2021
Of mice and men and their different tolerance to pathogens
Infectious Disease & AMR

Of mice and men and their different tolerance to pathogens

MAR 23, 2021
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis
Infectious Disease & AMR

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

MAR 16, 2021